Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for thrombotic thrombocytopenic purpura refractory to plasma exchange
IRCT2017012232125N1Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in thrombotic thrombocytopenic purpura (TTP), sponsored by Isfahan University of Medical Sciences. Started Mar 2010; status: completed.
02
Drugs
rituximab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on IRCT2017012232125N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017012232125N1.